logo
Share SHARE
FONT-SIZE Plus   Neg

Merck Reports New Data From 2 Pivotal Phase III Efficacy Trials For Suvorexant

Merck (MRK) announced new data from two pivotal Phase III efficacy trials for suvorexant, the investigational medicine company is developing for the treatment of insomnia.

In the studies, suvorexant significantly reduced the time it took patients to fall asleep and increased the time that patients stayed asleep as early as the first night and at the three-month time point compared to placebo. Merck noted that the investigational medicine met statistical significance for all primary endpoints except for one measurement at month 3 in one of the trials. These late-breaking data were presented today at SLEEP 2012, the 26th Annual Meeting of the Associated Professional Sleep Societies.

Darryle Schoepp, senior vice president and head of Neuroscience and Ophthalmology franchise, Merck Research Laboratories, stated, "Suvorexant approaches insomnia differently than other medicines because it helps patients to sleep by targeting and blocking orexins, which play a role in keeping people awake. We're excited about the Phase III results and the potential of suvorexant to become the first in a new class of medicines to help patients with insomnia."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Facebook Inc. has acquired anonymous social networking app tbh for an undisclosed sum and plans to operate it as a standalone app. The acquisition is part of Facebook's efforts to appeal to teenagers. Techcrunch reported that Facebook paid less than $100 million for the acquisition and the deal will not require any regulatory approval. Cruise itineraries in the Caribbean islands are almost back to business after the hurricanes Irma and Maria blasted through some islands. The Florida-Caribbean Cruise Association announced on a press call Monday that the hardest hit major ports, St. Thomas and St. Croix in the U.S. Virgin Islands, and St. Maarten and San Juan, Puerto Rico, are expected to open by the end of November. Banking major Goldman Sachs Group Inc. (GS) reported Tuesday profit for the third-quarter that declined 3 percent from last year. But, quarterly net revenues increased 2 percent. Both earnings per share and revenues topped analysts' expectations.
comments powered by Disqus
Follow RTT